
Italia
Maggiori informazioni ?
Contattaci
You are here
bioMérieux – 2020 Financial Results
24 Febbraio, 2021
bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.
17 Novembre, 2020
Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.
First-Half 2020 Results
02 Settembre, 2020
Second-Quarter 2020 Business Performance Preannouncement
15 Luglio, 2020
BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked
15 Luglio, 2020
CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®
27 Maggio, 2020